A newly reformed National Cancer Board has met for the first time, marking a significant step in the government's efforts to improve cancer diagnosis, treatment and long-term care across England.
The independent board has been tasked with monitoring progress against more than 100 commitments outlined in the National Cancer Plan and will play a central role in holding the healthcare system accountable for delivering improved outcomes for cancer patients.
Its remit includes reviewing performance in early diagnosis, treatment delivery and quality of life measures, while identifying areas that are falling behind and advising ministers on where further intervention is required.
A key feature of the board is its dedicated focus on some of the most challenging areas of cancer care. Expert leads have been appointed to oversee rare cancers, including brain tumours, cancer services for children and young people, and efforts to tackle inequalities in access to care and outcomes.
The launch comes amid signs of improving cancer performance. According to the government, all three national cancer standards are performing better than they were a year ago. Around 250,000 more people have either received a timely cancer diagnosis or had cancer ruled out over the past year compared with the year before the General Election.
Secretary of State for Health and Social Care Yvette Cooper said:
“Most families are affected by cancer at some point in our lives. That is why our National Cancer Plan is so important to provide earlier diagnosis, more advanced treatment and improve outcomes for everyone affected by cancer.
“The newly established, independent National Cancer Board will help scrutinise our progress, identify the areas that need most attention, and ensure the voice of cancer patients is constantly heard.
“I look forward to working with Anita Charlesworth and her team to deliver the change that every person in our country wants to see, and from which millions of our loved ones will benefit in the years to come.”
The board will be jointly led by independent co-chair Anita Charlesworth and Mark Cubbon from NHS England and the Department of Health and Social Care. Ministers say the arrangement is designed to provide greater transparency and reassure patients that progress is being objectively assessed.
Supporting the leadership team are:
- Dr Rob Metcalf, Clinical Lead for Rare Cancers
- Dr Dianne Addei, Lead for Cancer Inequalities
- Ashley Ball-Gamble, Lead for Children and Young People's Cancers
The board is expected to meet quarterly and publish an annual assessment of progress. A more comprehensive review will be carried out after three years, providing recommendations on whether the National Cancer Plan requires strengthening or updating.
Published in February 2026, the National Cancer Plan set an ambitious target of ensuring that three in four people diagnosed with cancer are cancer-free or living well five years after diagnosis by 2035.
Alongside performance improvements, the government has begun delivering several major commitments from the plan. These include expanding national lung cancer screening programmes, increasing capacity through Community Diagnostic Centres, broadening access to innovative cancer treatments and research opportunities, and strengthening support services for young people, rare cancer patients and those living with and beyond cancer.
Prevention also remains a major focus. Ministers point to the Tobacco and Vapes Act, which aims to create the UK's first smoke-free generation, alongside continued investment in screening initiatives and wider access to advanced radiotherapy treatments.
For NHS leaders and healthcare managers, the National Cancer Board is set to become a key mechanism for measuring whether ambitious policy commitments are translating into tangible improvements in patient outcomes and experience.
Image credit: iStock
